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Abstract
The mammographic screening debate has been
running for decades. The temperature of this debate
is unusually high, and all participants, regardless of
viewpoint, seem to have a conflict of interest. Another
unusual aspect of this debate is the focus on study
design, and in particular on designs that some think
exceeded their usefulness decades ago. What are the
questions that remain to be answered in this debate?
Are there methodological issues that have not been
adequately addressed? Do we have the right tools to
provide up-to-date answers to how women can best
protect themselves against dying from breast cancer?
This commentary discusses some of the current
issues.
See related Opinion articles http://www.
biomedcentral.com/1741-7015/10/106 and http://
www.biomedcentral.com/1741-7015/10/163
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Background
Over the past decades, much has been written about the
benefits and harms of mammographic screening. Although
many debates have raged in medicine, this debate has cer-
tain bizarre aspects. For one, the temperature has always
been exceedingly high. It has been argued that this is
because the proponents have their livelihood dependent
on screening, and thus strong conflicts of interest. Their
opponents, on the other hand, might claim they are simply
defending women, and specifically, women’s breasts. Or
are they? Careers have been built around this sole issue:
defending the integrity of women’s breasts. Perhaps we
will not move forward until we recognize that both sides
have conflicts of interest. As such this area is no different
than many other areas of medicine.
Consistent with this was the definition of ‘indepen-
dent’ of the recently converged independent panel in the
UK that were asked to evaluate the benefits and harms
of mammographic screening. In their report [1], the
authors explained their independence by the fact that
none of them had previously published on mammo-
graphic screening. Thus, apparently, only virgin writers
are truly independent in this debate.
Another strange aspect of the screening debate is the
discussion of study design, exemplified by two recent
papers in BMC Medicine [2,3]. Based on what we teach
our medical and public health students, this debate makes
little sense. Our students are taught that there is a strong
hierarchy in study designs. Randomized clinical trials are
time consuming and expensive, but represent the gold
standard. Thereafter come properly performed cohort stu-
dies, then modern (incidence-based) case-control studies,
then the cumulative-based case-control studies and cross-
sectional studies. At the bottom of the list are the ecologic
studies, studies based on aggregate numbers on a popula-
tion, such as studies of trends over time. These studies
have well described biases. Conclusions drawn from these
studies should not, according to textbooks in epidemiolo-
gic methods [4], be used to draw inferences at the biologi-
cal or individual level.
Researchers in medicine and public health tend to move
up in this hierarchy of study designs when addressing a
hypothesis, although not all hypotheses reach clinical
trials. In mammographic screening, the trials were per-
formed more than 30 years ago. Because these found that
screening reduced mortality of breast cancer, several coun-
tries introduced organized screening programs [5]. The
question then became whether we would see as strong
protective effects in the screening programs in the general
population as had been reported from the clinical trials.
The women who participate in clinical trials may differ
from the population at large on a number of key prognos-
tic variables, partly because of the strict exclusion criteria
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in clinical trials. The normal procedure in medicine is then
to conduct observational studies, such as cohort or case-
control studies with individual data to address this issue.
However, one of the ongoing debates in mammographic
screening is puzzling, and it is difficult to understand why
this would move the field forward. The discussion is not
whether observational studies confirm the effect found in
clinical trials, in fact there seems to be agreement that
they do. Instead it is the bottom part of the hierarchy of
study designs that is being discussed. There are actual pro-
ponents for the bottom level design, as exemplified by
Autier and Boniol [3]. Their argument is simply put that
because cohort studies and case-control studies can be
biased, we should use ecological studies. The problem
with this argument is that if cohort and case-control stu-
dies can be biased, ecological studies have worse problems,
as they do not have information on each individual [4].
Individuals are not classified correctly and even strong
associations can be missed. The UK panel [1] simply
ignored these studies in their summary as being ‘not
helpful’.
Puliti and Zappa [2] argue that studies with data at the
individual-level (case-control and incidence-based mortal-
ity studies) should be used. This is a conclusion that fits
with the classical hierarchy of study designs, and therefore
may seem obvious. However, even so it is important to
acknowledge the limitations of both case-control and
cohort studies and to better understand how the biases
work in such study designs, and how they should be
corrected.
Autier and Boniol [3] discuss one important bias, the
self-selection bias in case-control and cohort studies.
Screening participants are healthier than non-participants.
Thus even in the absence of screening, the screening parti-
cipants would have had lower mortality than non-screen-
ing participants. The issue is how to correct for this.
Autier and Boniol show an example of when the correc-
tion proposed by Duffy and colleagues [6] can go wrong.
This is a good start, but Autier and Boniol did not include
the most obvious solution to this problem. Those who
conduct case-control or cohort studies simply need to be
sensible about their adjustment. If the estimated correc-
tion factor from one’s study is unreasonably low compared
to previous estimates, then be cautious, as it may be
wrong, and one needs to discuss how the results change if
the correction factor changes. In Autier and Boniol’s
paper, the correction factor in their example (Dr in their
paper, relative risk of breast cancer death for non-com-
pliers compared to a non-invited comparison group) of
1.07 was too low, but if the investigators had used Duffy et
al.’s estimate based on clinical trials, which was 1.36 [6],
the bias would have been minimal.
The recently published UK report [1] concluded that
although most case-control studies and cohort studies
tried to control for possible biases, and although the
results were in the same direction as the randomized
clinical trials, there was some concern that residual bias
could have inflated the estimates from these studies. In
the end the UK panel only used results of randomized
clinical trials, the most stringent in the hierarchy of
study designs.
The independent UK panel concluded that ‘screening
reduces breast cancer mortality but that some overdiag-
nosis occurs’ [1]. Specifically they concluded that screen-
ing confers a 20% reduction in breast cancer mortality,
and that the overdiagnosis is 19% during the screening
period or 11% over long term. The main challenge is that
while all detected cancers will be treated, we do not yet
know which of the cancers would kill the woman if left
untreated. Although we have learned a substantial
amount about breast cancer subtypes and prognosis over
the past 12 years, the number of subtypes continues to
rise [7]. We do not yet have adequate clinical markers for
these subtypes, or even prognostic markers that can
accurately classify a patient as needing treatment or not.
There is a strong need for additional screening methods
to better differentiate cancers and specifically identify the
cancers that will kill.
In assessing the overall effect of screening on mortality,
the independent UK panel concluded that the best stu-
dies were old trials, studies conducted 30 or so years ago.
Much has changed in both breast cancer risk factors and
treatment over time. Are data from when the current
screening participants were in their teens ideal to express
what these women should do to avoid dying from breast
cancer today? How long should we continue to use such
old data as the best estimate for how mammographic
screening affects breast cancer mortality? When will both
sides agree that this is unwise?
The obvious alternative to rehashing old data is to force
screening proponents and opponents to work together to
identify the best way of using current individual based
data to address the issues. A challenge is whether we have
identified all the limitations of our best observational ana-
lytic designs, that is, cohort and case-control studies, and
when current bias adjustments are inadequate. If the pro-
screening side ignores these biases, or both sides present
them too simplistically, then we will get nowhere. We
ought to instead create scenarios that both sides recognize
represent real problems with cohort and case-control stu-
dies, and then address each specific problem analytically,
rather than going back to ecological designs.
Future directions and conclusions
Currently there are a number of new diagnostic methods
being introduced in the clinic, and an array of possible
prognostic or subtype markers that may reach the clinic
soon. Although, this has the potential of improving breast
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cancer screening, we will need to evaluate which combi-
nation of screening and prognostic markers are cost effi-
cient in large screening programs. Such evaluations can
be performed in stringent trials, but there is a strong
need for us to do this continuously in observational stu-
dies based on individual-level data. It will then be impor-
tant that we have the adequate epidemiological and
statistical tools to test these stringently. To move forward
in this endeavor, it is useful with a continuous debate of
these issues in mammographic screening, as long as the
debate focuses on the real issues, and not on whether
one’s side is right or wrong.
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